Literature DB >> 32693062

Leukemia-Associated Rho Guanine Nucleotide Exchange Factor and Ras Homolog Family Member C Play a Role in Glioblastoma Cell Invasion and Resistance.

Zonghui Ding1, Zhiwan Dong2, Yuping Yang2, Shannon P Fortin Ensign3, Hemragul Sabit4, Mitsutoshi Nakada4, Rosamaria Ruggieri2, Jean M Kloss1, Marc Symons2, Nhan L Tran5, Joseph C Loftus6.   

Abstract

Glioblastoma (GBM) is the most common primary malignant brain cancer in adults. A hallmark of GBM is aggressive invasion of tumor cells into the surrounding normal brain. Both the current standard of care and targeted therapies have largely failed to specifically address this issue. Therefore, identifying key regulators of GBM cell migration and invasion is important. The leukemia-associated Rho guanine nucleotide exchange factor (LARG) has previously been implicated in cell invasion in other tumor types; however, its role in GBM pathobiology remains undefined. Herein, we report that the expression levels of LARG and ras homolog family members C (RhoC), and A (RhoA) increase with glial tumor grade and are highest in GBM. LARG and RhoC protein expression is more prominent in invading cells, whereas RhoA expression is largely restricted to cells in the tumor core. Knockdown of LARG by siRNA inhibits GBM cell migration in vitro and invasion ex vivo in organotypic brain slices. Moreover, siRNA-mediated silencing of RhoC suppresses GBM cell migration in vitro and invasion ex vivo, whereas depletion of RhoA enhances GBM cell migration and invasion, supporting a role for LARG and RhoC in GBM cell migration and invasion. Depletion of LARG increases the sensitivity of GBM cells to temozolomide treatment. Collectively, these results suggest that LARG and RhoC may represent unappreciated targets to inhibit glioma invasion.
Copyright © 2020 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32693062      PMCID: PMC7527857          DOI: 10.1016/j.ajpath.2020.07.005

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  64 in total

1.  Leukemia-associated Rho guanine nucleotide exchange factor (LARG) links heterotrimeric G proteins of the G(12) family to Rho.

Authors:  S Fukuhara; H Chikumi; J S Gutkind
Journal:  FEBS Lett       Date:  2000-11-24       Impact factor: 4.124

2.  Clonogenic assay of cells in vitro.

Authors:  Nicolaas A P Franken; Hans M Rodermond; Jan Stap; Jaap Haveman; Chris van Bree
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 3.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

Review 4.  Structure and function of heterotrimeric G protein-regulated Rho guanine nucleotide exchange factors.

Authors:  Mohamed Aittaleb; Cassandra A Boguth; John J G Tesmer
Journal:  Mol Pharmacol       Date:  2009-10-30       Impact factor: 4.436

5.  Gα13/PDZ-RhoGEF/RhoA signaling is essential for gastrin-releasing peptide receptor-mediated colon cancer cell migration.

Authors:  Maulik Patel; Takeharu Kawano; Nobuchika Suzuki; Takao Hamakubo; Andrei V Karginov; Tohru Kozasa
Journal:  Mol Pharmacol       Date:  2014-06-23       Impact factor: 4.436

6.  Dichotomy of astrocytoma migration and proliferation.

Authors:  A Giese; M A Loo; N Tran; D Haskett; S W Coons; M E Berens
Journal:  Int J Cancer       Date:  1996-07-17       Impact factor: 7.396

7.  Acute activation of β2-adrenergic receptor regulates focal adhesions through βArrestin2- and p115RhoGEF protein-mediated activation of RhoA.

Authors:  Xiaojie Ma; Yu Zhao; Yehia Daaka; Zhongzhen Nie
Journal:  J Biol Chem       Date:  2012-04-12       Impact factor: 5.157

8.  Small-Molecule Protein-Protein Interaction Inhibitor of Oncogenic Rho Signaling.

Authors:  Dario Diviani; Francesco Raimondi; Cosmo D Del Vescovo; Elisa Dreyer; Erica Reggi; Halima Osman; Lucia Ruggieri; Cynthia Gonano; Sabrina Cavin; Clare L Box; Marc Lenoir; Michael Overduin; Luca Bellucci; Michele Seeber; Francesca Fanelli
Journal:  Cell Chem Biol       Date:  2016-09-01       Impact factor: 8.116

9.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

10.  RSK2 drives cell motility by serine phosphorylation of LARG and activation of Rho GTPases.

Authors:  Geng-Xian Shi; Won Seok Yang; Ling Jin; Michelle L Matter; Joe W Ramos
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-26       Impact factor: 11.205

View more
  1 in total

1.  Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies.

Authors:  Kate Connor; David W Murray; Monika A Jarzabek; Nhan L Tran; Kieron White; Patrick Dicker; Kieron J Sweeney; Philip J O'Halloran; Brian MacCarthy; Liam P Shiels; Francesca Lodi; Diether Lambrechts; Jann N Sarkaria; Raymond M Schiffelers; Marc Symons; Annette T Byrne
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.